Zhi Tong Cai Jing·2025-08-18 08:48Core Viewpoint - China Biopharmaceutical (01177) reported a revenue of RMB 17.57 billion for the six months ending June 30, 2025, representing a year-on-year increase of 10.7% [1] Financial Performance - The profit attributable to equity holders of the parent company was RMB 3.389 billion, an increase of 12.31% year-on-year [1] - Profit from continuing operations attributable to equity holders was RMB 3.39 billion, showing a significant increase of 140.2% year-on-year [1] - Basic earnings per share were 18.82 cents, with an interim dividend proposed at 5 Hong Kong cents per share [1] Product Development - During the reporting period, the company received NMPA approval for two innovative products: Putan Ning (Meloxicam Injection (II)) and Anqi Xin (Recombinant Human Coagulation Factor VIIa Injection) [1] - Revenue from innovative products reached RMB 7.8 billion in the first half of 2025, reflecting a year-on-year growth of 27.2% [1] - The company also received NMPA approval for five generic drugs, with overall revenue from generics maintaining positive growth in the first half of 2025 [1] Research and Development - The company places significant emphasis on research and development, viewing it as the foundation for sustainable growth [1] - Research and development costs amounted to approximately RMB 3.188 billion, accounting for about 18.1% of the company's revenue [1] - Including capitalized R&D expenditures, approximately 95.7% of total R&D costs have been recognized in the income statement [1]